Menu Search
Equities

Bioton SA

  • Add to watchlist
  • Add to portfolio
  • Add an alert
0DTR:LSE

Bioton SA

Actions
  • Price (PLN)--
  • Today's Change--
  • Shares traded--
  • 1 Year change--
  • Beta0.5082
Data delayed at least 20 minutes, as of Apr 01 2020.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Bioton SA is a Poland-based company active in the pharmaceutical sector. The Company is engaged in research, development and wholesale trade of pharmaceutical and biotechnological products. The Company's portfolio consists of oral hypoglycemic drugs (metformin and glimepride) as well as recombinant human insulin in pharmaceutical substance form and for injections. Additionally, the Company provides advertising services. As of December 31, 2011, the Company formed a capital group and operated through its subsidiaries, including BIOTON TRADE Sp. z o.o., Mindar Holdings Ltd, Germonta Holdings Ltd, Tricel SA, SciGen Ltd and BioPartners Holdings AG, among others. On June 12, 2014, it sold a 50% stake in Copernicus Sp. z o.o.

  • Revenue in PLN (TTM)295.81m
  • Net income in PLN-2.82m
  • Incorporated2004
  • Employees363.00
  • Location
    Bioton SAul. Staroscinska 5WARSZAWA 02-516PolandPOL
  • Phone+48 227214000
  • Fax+48 227211333
  • Websitehttps://bioton.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.